Summary
Danaher Corporation reported a 7.5% decrease in total revenue for the second quarter of 2023 compared to the prior year, with core sales down 7.0%. This decline was primarily driven by reduced demand for COVID-19 related products across its Biotechnology and Diagnostics segments, as well as a significant drop in China's Biotechnology segment due to a deteriorating funding environment. Despite the revenue headwinds, the company continues to generate substantial operating cash flow, with $3.9 billion for the first six months of 2023. Danaher is also progressing with its plan to separate its Environmental & Applied Solutions (EAS) segment into a new publicly traded company, Veralto Corporation, expected in the fourth quarter of 2023. While the overall revenue picture shows a year-over-year decline, it's important to note that price increases contributed positively to sales, partially offsetting volume declines. The company is actively managing its cost structure in response to changing demand, particularly in its Diagnostics and Biotechnology segments. Investors should monitor the impact of the EAS separation, ongoing demand normalization post-COVID, and the broader economic environment on future performance.
Financial Highlights
51 data points| Revenue | $5.91B |
| Cost of Revenue | $2.59B |
| Gross Profit | $3.32B |
| R&D Expenses | $361.00M |
| SG&A Expenses | $1.79B |
| Operating Income | $1.16B |
| Interest Expense | $67.00M |
| Net Income | $1.11B |
| EPS (Basic) | $1.50 |
| EPS (Diluted) | $1.49 |
| Shares Outstanding (Basic) | 737.30M |
| Shares Outstanding (Diluted) | 744.70M |
Key Highlights
- 1Total revenue decreased by 7.5% year-over-year to $7.16 billion in Q2 2023, with core sales down 7.0%.
- 2Net earnings attributable to common stockholders were $1.1 billion, or $1.49 per diluted share, a decrease from $1.7 billion, or $2.25 per diluted share, in Q2 2022.
- 3The Biotechnology segment experienced a significant sales decline of 17.0% (16.5% core sales) primarily due to reduced demand for COVID-19 related therapeutics and vaccines, and a deteriorating funding environment in China.
- 4The Diagnostics segment saw a 13.0% decrease in total sales (11.5% core sales), largely driven by lower demand for COVID-19 molecular diagnostic tests.
- 5Life Sciences segment showed resilience with a 5.5% increase in total sales (5.5% core sales), driven by demand in research and academic markets.
- 6The company generated $3.9 billion in operating cash flow for the first six months of 2023.
- 7Danaher plans to separate its Environmental & Applied Solutions (EAS) business into a new company, Veralto Corporation, in the fourth quarter of 2023.